Biotech Caught Between AI Momentum and Political Turbulence — This Week in Biotech #56

Subscribe to Biotech Blueprint, FREE weekly newsletter HERE. This week, Biotech Blueprint breaks down the crosswinds shaping the industry:– Novo Nordisk doubles down on AI drug discovery with an $812M Deep Apple partnership– The FDA approves UroGen’s bladder cancer drug Zusduri, the first non-surgical option for NMIBC– Gilead’s HIV program hits a clinical hold, but shares rebound as lenacapavir’s PDUFA nears– RFK Jr. removes the entire CDC vaccine panel, replacing members with mRNA skeptics– Senators Sanders and King reignite the push to ban direct-to-consumer drug ads– CRISPR Therapeutics rides the FDA’s accelerated approval momentum– Vaxart surges on promising data for its oral norovirus vaccineSubscribe to stay ahead of the science, policy, and market signals shaping biotech.

There are no comments yet.

Please log in to write the first comment.